- Raw materials
- Barbiturates
- Pyrithyldione
Pyrithyldione API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Pyrithyldione | CAS No: 77-04-3 | GMP-certified suppliers
A medication that functions as a central nervous system depressant with potential hypnotic and sedative effects for managing sleep and anxiety-related conditions.
Therapeutic categories
Product Snapshot
- Pyrithyldione is an oral small molecule formulation
- It is primarily investigated for central nervous system-related therapeutic applications
- The compound is currently in the experimental stage with no approved marketing authorization in key regulatory markets
Clinical Overview
Although specific clinical indications and pharmacodynamics data are not well documented, pyrithyldione has historically been investigated for its properties as a hypnotic and sedative agent. It is categorized as a psycholeptic, suggesting potential use in modulating nervous system activity to induce sedation or sleep. However, this compound remains experimental and has not received formal regulatory approval for clinical use.
The precise mechanism of action for pyrithyldione has not been established in the current literature. Given its classification and chemical family, its pharmacological effects are likely mediated through modulation of the central nervous system, although exact receptor targets or pathways are not reported.
Key absorption, distribution, metabolism, and excretion (ADME) parameters of pyrithyldione have not been extensively characterized, limiting comprehensive understanding of its pharmacokinetic profile. This gap restricts clear evaluation of dosing regimens or potential drug interactions.
Safety and toxicity information for pyrithyldione is sparse. As an experimental compound with CNS depressant effects, potential risks may include sedation-related adverse effects, but definitive clinical safety data are unavailable. No notable commercial brands or approved products containing pyrithyldione exist in current therapeutic markets.
For pharmaceutical formulation and sourcing, pyrithyldione requires thorough chemical characterization and stringent quality control to ensure purity and stability. Given its experimental status and limited clinical application, sourcing should prioritize suppliers that provide validated analytical data and comply with relevant regulatory standards for investigational compounds.
Identification & chemistry
| Generic name | Pyrithyldione |
|---|---|
| Molecule type | Small molecule |
| CAS | 77-04-3 |
| UNII | 8AB20823CK |
| DrugBank ID | DB13331 |
Formulation & handling
- Pyrithyldione is a small molecule suitable for oral formulations given its moderate water solubility and LogP.
- Its dihydropyridine structure suggests potential sensitivity to oxidative degradation, warranting consideration of antioxidative excipients.
- Stable under standard conditions but should be protected from prolonged exposure to light and moisture during handling.
Regulatory status
Pyrithyldione is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
